Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 summary

Strategic focus and platform differentiation

• Focused on developing oral medicines using targeted protein degradation, primarily in immunology over the past five years.

• Platform enables targeting previously undruggable proteins, especially transcription factors, with high specificity and potency.

• Emphasizes rigorous target selection based on human genetics, disease impact, and pathway validation.

• Differentiation includes robust translation from preclinical to clinical data and catalytic drug action with minimal off-target effects.

STAT6 program and clinical progress

• STAT6 chosen for its central role in type II inflammation and strong validation from upstream biologics like Dupilumab.

• STAT6 degraders offer complete pathway blockade with low drug exposure, potentially outperforming inhibitors.

• Healthy volunteer studies showed 90%+ STAT6 degradation, robust biomarker inhibition, and safety comparable to placebo.

• Phase 1b in atopic dermatitis aims to confirm target degradation, inform phase 2b dosing, and demonstrate clinical activity within 28 days.

Development plans and pipeline expansion

• Parallel phase 2b studies planned for atopic dermatitis and asthma to expedite registration and broaden indications.

• IRF5 program targets diseases like lupus, RA, and IBD, with phase I trials starting early next year.

• Preclinical pipeline includes undisclosed programs and partnerships with Sanofi, Regeneron, and Gilead, with updates expected next year.